These preclinical in vitro and in vivo findings demonstrate that co-treatment with DZNep and PS is an active combined epigenetic therapy worthy of further in vivo testing against MCL.
4 methyltransferase (KMTase) activity of PRC2 (9) . EZH2 is a KMTase that mediates epigenetic silencing of PRC2 target genes by inducing tri-methylation (3Me) of K27 on histone H3 (3MeK27H3) in the chromatin (9, 10) . EZH2 overexpression in transformed cells promotes cell proliferation and aggressiveness (11) (12) (13) . In hematologic malignancies, PRC2 regulates the expression of HOX genes and epigenetically represses genes including tumor suppressor genes p16 (CDKN2A) and p14 (ARF) (14) .
EZH2 was shown to be preferentially overexpressed in proliferating but not resting MCL cells (15) .
Recently, in lymphomagenesis, EZH2 mediated gene silencing in germinal center B cells was shown to contribute to cell proliferation (16) . Somatic gain of function mutations in tyrosine 641 (Y641C) in EZH2 have also been noted to selectively alter PRC2 catalytic activity and drive hyper-trimethylation of H3K27 in germinal center B cell lymphoma, thereby identifying EZH2 as a potentially attractive therapeutic target (17) (18) (19) (20) . PRC2 mediated trimethylation of H3K27 also recruits the muti-protein PRC1 complex, consisting among others of B lymphoma Mo-MLV insertion region 1 homolog (BMI1), as well as RING1 and RING2 proteins, which mediate ubiquitylation of histone H2A on K119 associated with gene repression (9, 14) . BMI1 represses CDKN2A and INK4A/ARF and cooperates with MYC in lymphomagenesis (14) . In addition, BMI1 locus has been shown to be amplified in MCL cells (21) .
EZH2 has also been reported to directly control DNA methylation through its association with and regulation of the activity of the DNA methyltransferases DNMT1, DNMT3a and DNMT3b (22, 23) .
However, genes silenced in cancer by 3MeK27H3 have been shown to be independent of promoter DNA methylation indicating that PRC2-mediated silencing could be an independent mechanism for suppression of tumor suppressor genes (TSGs) (24) . Consistent with this, both DNA methylation and transcriptional silencing of PRC2 target genes persists when EZH2 expression is depleted (25, 26) .
3-deazaneplanocin A (DZNep) is the cyclopentanyl analog of 3-deazaadenosine that inhibits the activity of S-adenosyl-L-homocysteine (AdoHcy) hydrolase, the enzyme responsible for the reversible hydrolysis of AdoHcy to adenosine and homocysteine (27) . DZNep has also been shown to deplete the expression levels of EZH2 and SUZ12, with concomitant loss of trimethylation of K27 on histone H3
and re-expression of epigenetically silenced targets such as the F-box protein FBXO32-a component of 5 MCL cells (29) (30) (31) . In AML cells, treatment with PS was shown to deplete the levels of EZH2 and SUZ12, as well as reduce the 3MeK27H3 mark on the chromatin (32) . PS treatment also depleted the levels of DNMT1 and disrupted its binding to EZH2 in AML cells (33, 34) . In addition, co-treatment with DZNep and PS was shown to be more effective against the epigenetic targets and synergistically induced apoptosis of AML cells (34) . In the present studies, we determined that treatment with DZNep depletes PRC2 complex proteins and induces cell cycle arrest and apoptosis of cultured and primary MCL cells. Our findings also demonstrate that the combined treatment of DZNep and PS causes more depletion of PRC2 complex proteins and induces synergistic apoptosis of cultured and primary MCL cells but not normal CD34 + bone marrow progenitor cells. In addition, co-treatment with DZNep and PS was more effective than each agent alone in inhibiting the in vivo tumor growth of JeKo-1 xenografts in NOD/SCID mice.
Materials and Methods:
Reagents Panobinostat (PS) was kindly provided by Novartis Pharmaceuticals, Inc. (East Hanover, NJ).
3-Deazaneplanocin A (DZNep) was acquired from the National Cancer Institute (Rockville, MD). Anti-BMI1, trimethylated K9 Histone H3, trimethylated K79 Histone H3, acetylated K16 Histone H4, acetylated K56 Histone H3, acetylated K27 histone H3 and trimethylated K4 Histone H3 antibodies were purchased from Millipore (Billerica, MA). Anti-EZH2, anti-SUZ12, anti-Cyclin D1, anti-Cyclin E, anti-PARP, and anti-Histone H3 antibodies were purchased from Cell Signaling (Beverly, MA). Antip27 KIP1 and anti-p16 antibodies were purchased from BD Transduction Labs (San Jose, CA). Anti-p21 and anti-DNMT1 antibodies were purchased from Abcam (Cambridge, MA). Anti-FBXO32 antibody was purchased from Santa Cruz Biotechnologies (Santa Cruz, CA). Anti-β-actin antibody was obtained from Sigma-Aldrich (St. Louis, MO).
Cell lines and cell culture Mantle cell lymphoma cell lines MO2058 were obtained and maintained as previously described (29, 30) . JeKo-1 and Z-138 cells were obtained from ATCC (Manassas, VA). Both cell lines were banked after receipt, and passaged for less than 6 months before use in these studies. The American Type Culture Collection characterizes cell lines using short tandem repeat polymorphism analysis. MCL cells were maintained in culture, as previously described (29, 30) . Logarithmically growing cells were exposed to the designated concentrations of DZNep and/or panobinostat. Following these treatments, cells were washed free of the drug(s) prior to the performance of the studies. PBS with 0.1% Triton X-100, RNAse A and propidium iodide and incubated in the dark at 37°C for 15 minutes. Cell cycle data were collected on a flow cytometer with a 488 nM laser and analyzed with ModFit 3.0, as previously described (34) .
Assessment of percentage non-viable cells Following treatment with DZNep and/or PS, non-viable
cells were determined by trypan blue dye uptake on a hemocytometer, as previously described (29, 30, 34) . Alternatively, cells were stained with propidium iodide and the percentages of non-viable cells were determined by flow cytometry.
RNA interference Small interfering RNAs against EZH2 were obtained from Dharmacon (Lafayette, CO). JeKo-1 cells were transfected with siRNA to a final concentration of 100 nM using an Amaxa Nucleofector device. Cells were incubated for 48-72 hours for detection of EZH2 knockdown.
Lentiviral shRNAs against EZH2 were obtained from Sigma-Aldrich (St. Louis, MO). JeKo-1 cells were transduced with lentivirus and incubated for 48 hours. Following this, cells were washed with complete media and incubated an additional 24 hours for immunoblot analyses or 72 hours to observe effects on cell proliferation, as previously described (34, 36) . SUZ12, EED, Cyclin D2, SMARCA2, TCF4 and EIF3A were performed on the resulting cDNA utilizing TaqMan probes from Applied Biosystems (Foster City, CA), as previously described (33, 34) .
RNA isolation and
Detection and analysis of hsa-miR-101 in MCL cells For detection of hsa-miR-101 in JeKo-1 and MO2058 cells, microRNAs were isolated with a kit from Applied Biosystems (Foster City, CA).
Enriched RNA was reverse transcribed with a stem loop primer included in the TaqMan hsa-miR101 microRNA assay following the manufacturer's protocol (Applied Biosystems, Foster City, CA).
Expression of hsa-miR101 was detected by qPCR with a TaqMan probe specific to hsa-miR-101.
Relative expression of hsa-miR101 was normalized against expression of 18S RNA. Cell lysis, histone isolation and protein quantitation Untreated or drug-treated cells were centrifuged and the cell pellets were resuspended in 200 µL of lysis buffer as previously described (33, 34) . Histones were extracted from untreated and treated cells as previously described (32) .
Chromatin immunoprecipitation and Polymerase Chain Reaction

SDS-PAGE and immunoblot analyses
Seventy five micrograms of total cell lysate was used for SDS-PAGE. Western blot analyses of DNMT1, EZH2, SUZ12, EED, 3MeK27H3, Acetyl K27H3, PARP, FBXO32, Cyclin E, p16, p21, and p27 were performed on total cell lysates as previously described (29, 30, 34) . Immunoblot analyses were performed three times, and the same immunoblot was probed with specific antisera or monoclonal antibodies. Representative blots were subjected to densitometric analysis where expression levels of β-actin were used as the control. Densitometry was performed using ). We selected the dose of DZNep that had been determined to be safe in previously reported studies and combined it with a dose of PS that we had previously reported to be safe and biologically effective (29, 38) . This study was performed in duplicate with similar results. Statistical Analysis Significant differences between values obtained in a population of mantle cell lymphoma cells treated with different experimental conditions were determined using the Student's ttest. For the in vivo mouse models, the final tumor volumes at the end of treatment were used to calculate the difference between mice treated with DZNep or PS alone versus mice treated with the combination using a two tailed t-test. P values of < 0.05 were assigned significance.
Results
Treatment with DZNep depletes PRC2 proteins EZH2 and SUZ12 levels and disrupts the PRC2
complex in MCL cells. Treatment with DZNep has been previously shown to deplete EZH2 and SUZ12 levels in breast cancer, colon cancer and leukemia cells (28, 34, 37) . Here, we determined the effect of Figure 1E ). DZNep-mediated alterations in the levels of PRC2 proteins and in the chromatin marks led to decline in the binding of EZH2 to its known target promoters, e.g., HOXA9, WNT1 and RUNX3, as discerned by chromatin immunoprecipitation (ChIP) analysis of the promoters of these genes ( Figure   2A ) (28, 34, 37) . Both in cultured and primary MCL cells, treatment with DZNep also reduced the levels of the PRC1 protein BMI ( Figure 1A and 1B). The effects of DZNep on PRC2 and PRC1 proteins and chromatin marks were associated with decline in the levels of Cyclin D1 and cyclin E, but increase in the levels of p27, p21, p16, and the pro-death F-Box protein FBXO32, an E3 ubiquitin ligase (28, 34) , in DZNep mediated induction of p16, p21, p27, and FBXO32 is mechanistically linked to depletion of EZH2 in MCL cells. To determine whether the DZNep-mediated decline in EZH2 was mechanistically linked to increase in the levels of p21, p27 and FBXO32, we also determined the effect of siRNA to EZH2 in JeKo-1 cells. Figure 4A demonstrates that, as compared to the control siRNA, treatment with siRNA to EZH2 for 48 hours depleted EZH2 mRNA, but modestly increased the levels of EED mRNA.
SUZ12 mRNA was unaffected (data not shown). Treatment with siRNA to EZH2 was associated with decline in protein levels of EZH2 and SUZ12 but not of EED ( Figure 4B ). In addition, there was no effect of EZH2 siRNA on the protein levels of DNMT1 and HDAC2, while HDAC1 levels were slightly increased ( Figure 4B ). Attenuation of PRC2 proteins by EZH2 siRNA and the impairment of the PRC2 complex activity were associated with decline in the levels of 3MeK27H3 but induction of acetylated K27H3 and 3Me H3K4 levels in MCL cells ( Figure 4C ). This was accompanied by increase in the levels of p16, p21 and p27, with modest decline in Cyclin D1 levels ( Figure 4C ). EZH2 siRNA treatment also induced the F-Box protein FBXO32 levels in MCL cells ( Figure 4C ). We also determined the effects of transduction of shRNA to EZH2 on the proliferation and apoptosis of MCL cells. Depletion of EZH2 and SUZ12 by EZH2 shRNA significantly inhibited cell proliferation without inducing apoptosis of MCL cells ( Figure 4D and data not shown).
Treatment with the pan-HDAC inhibitor panobinostat (PS) depletes PRC2 complex proteins with
concomitant decline in 3MeK27H3 in MCL cells. We next determined whether treatment with the pan-HDAC inhibitor PS would deplete the levels of EZH2 and SUZ12 with concomitant decline in the levels of 3MeK27H3 in MCL cells, as was observed in cultured and primary AML cells (32) . Figure 5A demonstrates that PS treatment depletes EZH2 and SUZ12 levels, as well as attenuates the levels of BMI1 and DNMT1 in MCL cells ( Figure 5A and Supplemental Figure S4C ). This was accompanied by depletion of 3MeK27H3 and marked up regulation of acetylated-K27H3 and acetylated-K16H4 in the MCL cells ( Figure 5B ). In addition, PS treatment also inhibited K119H2A ubiquitylation, possibly due to decline in PRC1 activity in MCL cells (9, 14) . Treatment with PS also significantly depleted the levels of Cyclin D1 in all three cell lines ( Figure 5A and Supplemental Figure 4C ). Consistent with previous reports, here also we observed that, in conjunction with its effects on epigenetic mechanisms, PS also induced apoptosis of the cultured MCL cells ( Figure 5C and 5D) (29) (30) (31) . Figure 5C ). This activity of the combination was also associated with greater attenuation of EZH2, SUZ12 and the 3MeK27H3 chromatin mark, with a concomitant, greater induction of 3MeK4H3 mark in the cultured MCL cells ( Figure 6C and Supplemental Figure 5A and 5B). Co-treatment with DZNep and PS also caused greater decline in 
Co-treatment with
DNMT1 levels. It is noteworthy that, as compared to each agent alone, combined treatment with DZNep and PS induced greater increase in the levels of FBXO32, p21 and p27 in the cultured MO2058 MCL Cells ( Figure 6C ). Similar effects were also observed in JeKo-1 and Z-138 cells (Supplemental Figure   5A ). 
Treatment with
Discussion
Deregulated epigenome plays a pathogenic role and contributes to the aggressive biology in human MCL (3, 7, 8, 14) . In this, the specific role of overexpression of the PRC2 and PRC1 proteins EZH2, SUZ12 and BMI1 has also been elucidated (3, 5, 7, 14) . Our present studies demonstrate that a Notably, the PRC1 protein BMI1 is commonly amplified and overexpressed in MCL cells (9, 14) . Our findings demonstrate that DZNep treatment also depleted BMI1, thereby affecting PRC1 activity in MCL cells. Although this was not studied here, DZNep may be exerting this effect on BMI1 levels by perturbing the recently described, EZH2-regulated miRs that regulate the expression of BMI1 (43) . By inhibiting both PRC2 and PRC1 activity, DZNep treatment reduced the levels of 3MeK27H3 and ubiquitylated-K119H2A chromatin marks, but increased the acetylation of K27H3, K56H3 and K16H4.
While the precise underlying mechanism for this is unknown, exposure to DZNep also increased the levels of 3MeK4H3 in MCL cells. Although its impact here is unknown, this is known to be a PRC1, and the notable alterations in the chromatin marks: decreased 3MeK27H3 and increased 3MeK4H3, are also likely to affect the bivalent chromatin mark, which is known to promote lineage differentiation in transformed stem cells (45) . While PRC2 is known to recruit DNMTs to the promoters of PRC2 target genes and PRC2 inhibition should affect DNA methylation of the target gene promoters, this was not the case for p16 gene promoter where CpG methylation was found to be unaffected by DZNep treatment. However, both EZH2 and BMI1-mediated chromatin effects have been implicated in the repression of Ink4a/Arf locus encoding p16 and ARF (p19) (46, 47) . Therefore, notwithstanding the absence of its effects on DNA methylation, it is not surprising that treatment with DZNep led to up regulation of p16 expression in MCL cells. BMI1 has also been shown to be required to reinforce bivalent domains at key gene loci for maintaining lineage specification poised for activation in hematopoietic stem cells (48) .
DZNep treatment in MCL cells increased the expression of the cell cycle inhibitory proteins p16, p21 and p27 in MCL cells and caused induction of the E3 ubiquitin ligase FBXO32 (28, 32, 34, 37) . DZNep induced FBXO32 levels were associated with decline in the levels of Cyclin E, which is known to be targeted by FBXO32 (28) . Induction of FBXO32 has also been shown to promote apoptosis (28, 33) . Searching for more specific and less toxic EZH2 antagonists is a clear priority but prototype, direct EZH2 antagonists are not yet available for testing.
As was reported for other cancer cell-types, treatment with PS also depleted EZH2, SUZ12 and BMI1 in MCL cells. Concomitantly, this was associated with decline in the 3MeK27H3 but increase in 3MeK4H3, acetylated-K27 H3 and acetylated-K16 H4 chromatin marks. PS treatment also inhibited H2A ubiquitylation, possibly due to decline in PRC1 activity in MCL cells (9, 14) . Importantly, 
